Clinical trials: Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
This is a Phase I, multicenter, open-label, two-stage study of APG-3288 monotherapy, aiming to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of APG-3288 administered orally once daily in patients…
- Conditions
- Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL, Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation), Relapsed/Refractory Mantle Cell Lymphoma (MCL)
- Trial name
- NCT07424833
- Testing
- APG-3288
- Where
- 6 sites in United States, China
- Volunteers
- 180 people
- Sponsor
- Ascentage Pharma Group Inc.
Diffuse Large B-cell Lymphoma
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic options of demonstrated clinical benefit.
- Trial name
- NCT02227251
- Testing
- Selinexor
- Where
- 175 sites in United States, Australia and 17 more
- Volunteers
- 244 people
- Sponsor
- Karyopharm Therapeutics Inc
Lymphoma, Large B-Cell, Diffuse
To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL
Part 1 (Phase Ib) Primary objective: To establish the maximum tolerated dose (MTD) of BI 836826 in combination with GemOx. Secondary objectives: To evaluate pharmacokinetics of BI 836826 when given in combination with GemOx and…
- Trial name
- NCT02624492
- Testing
- BI 836826, GemOx, Rituximab
- Where
- 7 sites in Belgium, Italy and 1 more
- Volunteers
- 21 people
- Sponsor
- Boehringer Ingelheim
Diffuse Large B-Cell Lymphoma
KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma
This study evaluates the addition of selinexor (KPT-330) to RICE chemotherapy in the treatment of relapsed and refractory aggressive B-Cell Lymphoma, with the goal of improved response rates (as compared to RICE chemotherapy…
- Trial name
- KPT-330+RICE (NCT02471911)
- Testing
- KPT-330, Rituximab, Etoposide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Weill Medical College of Cornell University
DLBCL
Evaluating the Treatment Outcomes of Tafasitamab in Patients With Relapsed/ Refractory Diffuse Large B-cell Lymphoma: a Real-world Evidence Study
To evaluate the efficacy of tafasitamab in patients with relapsed/ refractory diffuse large B-cell lymphoma *To evaluate best objective response rate (ORR)
- Trial name
- NCT07709624
- Testing
- Minjuvi
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- TTY Biopharm
RR DLBCL; PD-1; CD20
A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCL
This is an open-label, single-arm, and multicenter phase Ⅱ study designed to evaluate the efficacy and safety of F520 (PD-1) combined with F007(rituximab biosimilar) in patients with Relapsed/Refractory diffuse large B-cell…
- Trial name
- NCT05178836
- Testing
- F520+F007
- Volunteers
- 62 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
DLBCL - Diffuse Large B Cell Lymphoma
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of SCTB35 in Combination With Gemcitabine and Oxaliplatin vs Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory…
- Trial name
- NCT07570823
- Testing
- SCTB35 injection, Rituxumab, Gemcitabine
- Where
- China
- Volunteers
- 101 people
- Sponsor
- Sinocelltech Ltd.
Diffuse Large B-cell Lymphoma
Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Oral Lenalidomide is initiated on day 1 of cycle 1 at the dose of 20 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.
- Trial name
- NCT00968331
- Testing
- Lenalidomide plus Rituximab
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- University of Bologna
Lymphoma Nonhodgkin, Marginal Zone B Cell Lymphoma
A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
The goal of this Phase II single-arm, open-label clinical trial is to evaluate whether UF-KURE19, an autologous CD19-directed CAR-T cell therapy manufactured t…The goal of this Phase II single-arm, open-label clinical trial is to…
- Conditions
- Lymphoma Nonhodgkin, Marginal Zone B Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Follicular B-cell Non-Hodgkin's Lymphoma
- Trial name
- NCT07713459
- Testing
- CART Infusion
- Volunteers
- 105 people
- Sponsor
- Kure Cells, INC
CD5+ Relapsed/Refractory Hematopoietic Malignancies, Chronic Lymphocytic Leukemia (CLL)
Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies
Current treatments for relapsed/refractory hematopoietic malignancies such as B-cell lymphomas (BCLs) and peripheral T-cell lymphomas (PTCLs) are far from satisfactory.
- Conditions
- CD5+ Relapsed/Refractory Hematopoietic Malignancies, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), Diffuse Large B-cell Lymphoma (DLBCL)
- Trial name
- NCT04767308
- Testing
- CT125A cells, Cyclophosphamide, fludarabine
- Volunteers
- 18 people
- Sponsor
- Huazhong University of Science and Technology